Cost Differential of Immuno-Oncology Therapy Delivered at Community Versus Hospital Clinics

  • News

Oncology treatment advances continue to evolve at a rapid pace, with immuno-oncology (I-O) therapy at the forefront given its efficacy and tolerability across different tumor types. The last few years have seen fast-track approvals, promising clinical responses, and significant investment from both pharmaceutical companies and venture capital firms. 

The site of cancer care delivery has been shown to be associated with differences in cost of care; a recent systematic literature review revealed that costs were substantially higher for patients treated in hospital-based versus community-based practices.

Read the full article here.

Back To News